Exome Asset Management LLC
13F Reported Value
ⓘ$193.3M
incl. option notional
Equity Holdings
ⓘ$169.9M
Option Notional
ⓘ$23.4M
$19.0M puts / $4.4M calls
Holdings
56
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
Exome Asset Management LLC disclosed 56 positions worth $193.3M in its Form 13F-HR for Q1 2026 — $169.9M in common stock plus $23.4M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 8.6% of the equity portfolio, followed by $COGT and $ELVN. During the quarter the fund opened 23 new positions and exited 27 and a full exit from $WVE. The portfolio is most concentrated in Healthcare (98.1% of disclosed assets). All figures are sourced directly from Exome Asset Management LLC’s Form 13F-HR filing with the SEC under CIK 2011932.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- $14.6M45,469 sh
- —
Quality
$10.7M278,533 sh - —
Quality
$8.6M220,091 sh - 37.1
Quality
$8.3M110,064 sh SPDR SERIES TRUST PUT
—Quality
$7.7M60,000 sh- 36.1
Quality
$7.6M82,736 sh - 28.0
Quality
$6.8M103,718 sh - 89.3
Quality
$6.4M7,012 sh - 9.2
Quality
$6.2M279,176 sh - 31.7
Quality
$5.0M67,492 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $14.6M | 45,469 |
 Cogent Biosciences, Inc.$COGT | — | $10.7M | 278,533 |
 Enliven Therapeutics, Inc.$ELVN | — | $8.6M | 220,091 |
 IONIS PHARMACEUTICALS INC$IONS | 37.1 | $8.3M | 110,064 |
| SPDR SERIES TRUST PUT | — | $7.7M | 60,000 |
 Guardant Health, Inc.$GH | 36.1 | $7.6M | 82,736 |
 CYTOKINETICS INC$CYTK | 28.0 | $6.8M | 103,718 |
 ELI LILLY & Co$LLY | 89.3 | $6.4M | 7,012 |
 ALUMIS INC.$ALMS | 9.2 | $6.2M | 279,176 |
 BridgeBio Pharma, Inc.$BBIO | 31.7 | $5.0M | 67,492 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Exome Asset Management LLC's 56 positions.
Showing top 10 of 56 holdings.
Sector Allocation
Healthcare
$166.7M
Technology
$3.3M
Full Holdings — Exome Asset Management LLC (Q1 2026)
All 56 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $14.6M | 8.6% | -22% | — |
| 2 | $COGT | Cogent Biosciences, Inc. | $10.7M | 6.3% | -9% | — |
| 3 | $ELVN | Enliven Therapeutics, Inc. | $8.6M | 5.1% | -1% | — |
| 4 | $IONS | IONIS PHARMACEUTICALS INC | $8.3M | 4.9% | -6% | 37.1 |
| 5 | — | SPDR SERIES TRUST | $7.7M | — | NEW | — |
| 6 | $GH | Guardant Health, Inc. | $7.6M | 4.5% | -16% | 36.1 |
| 7 | $CYTK | CYTOKINETICS INC | $6.8M | 4.0% | -17% | 28 |
| 8 | $LLY | ELI LILLY & Co | $6.4M | 3.8% | -11% | 89.3 |
| 9 | $ALMS | ALUMIS INC. | $6.2M | 3.6% | -4% | 9.2 |
| 10 | $BBIO | BridgeBio Pharma, Inc. | $5.0M | 3.0% | -16% | 31.7 |
| 11 |  $VERA | Vera Therapeutics, Inc. | $4.6M | 2.7% | -8% | — |
| 12 |  $INSM | INSMED Inc | $4.4M | 2.6% | NEW | 29.4 |
| 13 |  $ELV | Elevance Health, Inc. | $4.3M | 2.5% | -15% | 59.4 |
| 14 |  $AGIO | AGIOS PHARMACEUTICALS, INC. | $4.2M | 2.5% | -9% | 26.3 |
| 15 |  $UTHR | UNITED THERAPEUTICS Corp | $4.2M | 2.5% | -8% | 80.1 |
| 16 |  $MLTX | MoonLake Immunotherapeutics | $4.0M | 2.4% | NEW | — |
| 17 | $CYTKPUT | CYTOKINETICS INC | $4.0M | — | NEW | 28 |
| 18 |  $NTRA | Natera, Inc. | $3.7M | 2.2% | +0% | 46.4 |
| 19 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $3.5M | 2.1% | NEW | 30.3 |
| 20 |  $UNH | UNITEDHEALTH GROUP INC | $3.5M | 2.0% | +120% | 66.8 |
| 21 |  $APLS | Apellis Pharmaceuticals, Inc. | $3.4M | 2.0% | -37% | 63.9 |
| 22 |  $VSTM | Verastem, Inc. | $3.4M | 2.0% | +58% | 40.8 |
| 23 |  $TXG | 10x Genomics, Inc. | $3.3M | 1.9% | -6% | 44.1 |
| 24 |  $BSX | BOSTON SCIENTIFIC CORP | $3.0M | 1.8% | NEW | 79.9 |
| 25 |  $ALKS | Alkermes plc. | $3.0M | 1.8% | NEW | — |
| 26 |  $ONCCALL | BeOne Medicines Ltd. | $3.0M | — | NEW | — |
| 27 |  $GLUE | Monte Rosa Therapeutics, Inc. | $3.0M | 1.7% | NEW | 18.1 |
| 28 |  $ISRG | INTUITIVE SURGICAL INC | $2.9M | 1.7% | +0% | 81.4 |
| 29 |  $ADAG | Adagene Inc. | $2.9M | 1.7% | -31% | — |
| 30 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $2.9M | 1.7% | -8% | 74.4 |
| 31 |  $CBIO | CRESCENT BIOPHARMA, INC. | $2.8M | 1.7% | NEW | 28 |
| 32 |  $RLAY | Relay Therapeutics, Inc. | $2.8M | 1.6% | NEW | 12.7 |
| 33 |  $MAZE | Maze Therapeutics, Inc. | $2.6M | 1.6% | NEW | 19.7 |
| 34 |  $CTMX | CytomX Therapeutics, Inc. | $2.5M | 1.4% | -30% | 19.1 |
| 35 |  $AVTX | Avalo Therapeutics, Inc. | $2.4M | 1.4% | NEW | 4.6 |
| 36 | $ALMSPUT | ALUMIS INC. | $2.3M | — | +97% | 9.2 |
| 37 |  $GKOS | GLAUKOS Corp | $2.2M | 1.3% | -34% | 39.2 |
| 38 |  $CRBP | Corbus Pharmaceuticals Holdings, Inc. | $2.2M | 1.3% | +68% | — |
| 39 |  $PEN | Penumbra Inc | $2.1M | 1.2% | -30% | 69.7 |
| 40 |  $SLNO | SOLENO THERAPEUTICS INC | $2.1M | 1.2% | NEW | 46.3 |
| 41 |  $LQDA | Liquidia Corp | $1.7M | 1.0% | -50% | 37.4 |
| 42 |  $ZBIO | Zenas BioPharma, Inc. | $1.6M | 0.9% | NEW | 14.4 |
| 43 | $LQDAPUT | Liquidia Corp | $1.5M | — | NEW | 37.4 |
| 44 |  $NBP | NovaBridge Biosciences | $1.4M | 0.8% | +15% | — |
| 45 |  $CNTAPUT | Centessa Pharmaceuticals plc | $1.4M | — | NEW | — |
| 46 |  $IDYACALL | IDEAYA Biosciences, Inc. | $1.3M | — | NEW | 10.5 |
| 47 | $IDYAPUT | IDEAYA Biosciences, Inc. | $1.3M | — | NEW | 10.5 |
| 48 |  $FDMT | 4D Molecular Therapeutics, Inc. | $1.2M | 0.7% | NEW | 23.2 |
| 49 |  $NXTC | NextCure, Inc. | $1.2M | 0.7% | -30% | — |
| 50 |  $PALI | PALISADE BIO, INC. | $1.1M | 0.6% | -21% | — |
| 51 |  $ESTA | ESTABLISHMENT LABS HOLDINGS INC. | $743,818 | 0.4% | +0% | 26.7 |
| 52 |  $TVTXPUT | Travere Therapeutics, Inc. | $594,200 | — | -73% | 39.2 |
| 53 |  $LPCN | Lipocine Inc. | $486,279 | 0.3% | NEW | — |
| 54 |  $ABUS | Arbutus Biopharma Corp | $339,678 | 0.2% | +0% | — |
| 55 |  $WVEPUT | Wave Life Sciences Ltd. | $217,500 | — | NEW | — |
| 56 |  $CMPXCALL | Compass Therapeutics, Inc. | $132,779 | — | NEW | — |
New Positions (23)
$INSM INSMED Inc$4.4M$MLTX MoonLake Immunotherapeutics$4.0M$CYTKPUT CYTOKINETICS INC$4.0M$RYTM RHYTHM PHARMACEUTICALS, INC.$3.5M$BSX BOSTON SCIENTIFIC CORP$3.0M$ALKS Alkermes plc.$3.0M$ONCCALL BeOne Medicines Ltd.$3.0M$GLUE Monte Rosa Therapeutics, Inc.$3.0M$CBIO CRESCENT BIOPHARMA, INC.$2.8M$RLAY Relay Therapeutics, Inc.$2.8M$MAZE Maze Therapeutics, Inc.$2.6M$AVTX Avalo Therapeutics, Inc.$2.4M$SLNO SOLENO THERAPEUTICS INC$2.1M$ZBIO Zenas BioPharma, Inc.$1.6MExited Positions (27)
$WVE Wave Life Sciences Ltd.
$AZN ASTRAZENECA PLC
$JAZZ Jazz Pharmaceuticals plc
$IMVT Immunovant, Inc.
$UHS UNIVERSAL HEALTH SERVICES INC
$IRON Disc Medicine, Inc.
$CELC Celcuity Inc.$TVTX Travere Therapeutics, Inc.
$DXCM DEXCOM INC
$IMCR Immunocore Holdings plc
$EWTX Edgewise Therapeutics, Inc.
$BLTE BELITE BIO, INC
$WAY Waystar Holding Corp.
$IRWD IRONWOOD PHARMACEUTICALS INC
$KPTI Karyopharm Therapeutics Inc.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Exome Asset Management LLC including:
Track Exome Asset Management LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Exome Asset Management LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Exome Asset Management LLC
13F Pro is an AI hedge fund tracker and stock research platform. For Exome Asset Management LLC (SEC CIK: 2011932), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Exome Asset Management LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.